Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases.
Oral delivery of natural active small molecules by polymeric nanoparticles for the treatment of inflammatory bowel diseases.
复制标题
DOI：
10.1016/j.addr.2021.113887
复制
发表时间：
2021-07
影响因子：
16.1
通讯作者：
Menghang Zu;Ya Ma;Brandon Cannup;Dengchao Xie;Yunjin Jung;Jinming Zhang;Chunhua Yang;Fei Gao
中科院分区：
文献类型：
--
作者：
Menghang Zu;Ya Ma;Brandon Cannup;Dengchao Xie;Yunjin Jung;Jinming Zhang;Chunhua Yang;Fei Gao
炎症性肠病(IBD)的发病率在全球范围内迅速上升。虽然已经做出了巨大的努力，但可用于IBD治疗的治疗方法有限。天然活性小分子(NASM)是大自然赐予人类的礼物，已被广泛应用于预防和缓解IBD，具有良好的生物相容性、药理活性和规模化生产潜力。口服给药途径是目前最常见、最容易接受的给药途径，但NASM经口服给药途径存在疏水性强、不稳定、生物利用度低等固有局限性，严重制约了其在IBD治疗中的临床应用。随着纳米技术的发展，聚合物纳米粒(NPs)提供了一个很有前途的平台，可以有效地包裹多功能的NASM，克服多种药物传递障碍，并将负载的NASM口服给靶组织或细胞，同时提高其稳定性和生物利用度。因此，NPs可以增强NASM对IBD的预防和治疗作用。在此，我们综述了聚合物基质载体、靶向药物递送配体和NASM的最新知识。我们还讨论了当前面临的挑战和未来的发展方向。
The incidence of inflammatory bowel disease (IBD) is rapidly rising throughout the world. Although tremendous efforts have been made, limited therapeutics are available for IBD management. Natural active small molecules (NASMs), which are a gift of nature to humanity, have been widely used in the prevention and alleviation of IBD; they have numerous advantageous features, including excellent biocompatibility, pharmacological activity, and mass production potential. Oral route is the most common and acceptable approach for drug administration, but the clinical application of NASMs in IBD treatmentviaoral route has been seriously restricted by their inherent limitations such as high hydrophobicity, instability, and poor bioavailability. With the development of nanotechnology, polymeric nanoparticles (NPs) have provided a promising platform that can efficiently encapsulate versatile NASMs, overcome multiple drug delivery barriers, and orally deliver the loaded NASMs to targeted tissues or cells while enhancing their stability and bioavailability. Thus, NPs can enhance the preventive and therapeutic effects of NASMs against IBD. Herein, we summarize the recent knowledge about polymeric matrix-based carriers, targeting ligands for drug delivery, and NASMs. We also discuss the current challenges and future developmental directions.